The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
On November 17th, 2022, MSF Access Campaign held a second roundtable on the need for transparency around clinical trials costs - why and how it could be done.
MSF, as a registered non-State actor with the WHO, expresses our strong concerns on the proposal put forward to supposedly improve NSA’s role, voice and contribution in WHO’s governing system.
MSF welcomes the report " Global strategy and plan of action on public health, innovation and intellectual property, for the period 2008-2022" and supports the extension of the plan of action on public health, innovation and IP until ...
MSF representatives are participating in the 148th session of the WHO executive board meetings and will be speaking on a number of topics. Click here to watch the livestream and read our statements below.
The World Health Assembly (WHA), the annual meeting of the world’s health ministers, is taking place virtually for the first time on 18 May 2020. MSF briefing document on agenda item: COVID-19 response Position paper on the sharing of ...